Loading patent…
AssigneeIchnos Sciences SA
InventorsLaure Bouchez, Blandine Pouleau, Marie-Agnes Doucey, Elie Dheilly, Stanislas Blein, Cian Stutz, Carole Estoppey, Jeremy Loyau, Thierry Monney, Camille Grandclement, Stefano Sammicheli
Estimating the term…
Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
A bispecific antibody comprising at least two binding portions, at least one of which binds to human CD38 and at least one of which binds to human CD47.
(canceled)
The method according to claim 18, wherein the proliferative disorder is multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, lymphoma, breast cancer such as Her2+ breast cancer, prostate cancer, cervical cancer, germinal center B-cell lympohoma or B-cell acute lymphoblastic leukemia, Chronic lymphocytic leukemia (CLL), Myelodisplastic syndrome (MDS), Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), High-grade serous ovarian carcinoma, or peritoneal cancer.
Dependencies are inferred from the claim text.